Rebecca Miksad, MD

Associate Professor, Hematology & Oncology

Rebecca Miksad
820 Harrison Avenue


Rebecca Miksad is a medical oncologist and health outcomes researcher who serves as senior medical director at Flatiron Health. In this role, Rebecca focuses on generating real-world evidence, establishing regulatory-grade quality standards and contributing to the development of clinically-relevant methods to real-world data evaluation and analyses.

Rebecca maintains a clinical practice at Boston Medical Center. A nationally recognized clinician and researcher, Rebecca regularly publishes in leading medical journals, serves on national committees and lectures internationally.

Prior to joining Flatiron Health, Rebecca was an assistant professor at Harvard Medical School, senior scientist at the Institute for Technology Assessment at Massachusetts General Hospital, and director of gastrointestinal oncology and gastrointestinal oncology clinical trials at Beth Israel Deaconess Medical Center (BIDMC). Rebecca’s academic research focused on improving cancer treatment decision-making through better characterization of patient outcomes and increasing relevance of clinical trial endpoints. Rebecca earned a BA cum laude in economics from Harvard University and an MD with honors in research from Cornell University. She was a resident in internal medicine at Cornell University/New York-Presbyterian Hospital, and completed hematology and medical oncology fellowships at Harvard Medical School/BIDMC. Rebecca earned a MMS from Harvard Medical School and an MPH in Clinical Effectiveness from the Harvard School of Public Health in clinical effectiveness (with an emphasis on decision science). She also completed a post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT).


  • Cornell University, MD
  • Harvard University, MMS/MMSc
  • Harvard School of Public Health, MPH
  • Harvard University, BA


  • Published on 4/17/2022

    Torres AZ, Nussbaum NC, Parrinello CM, Bourla AB, Bowser BE, Wagner S, Tabano DC, George D, Miksad RA. Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. Adv Ther. 2022 Jun; 39(6):2831-2849. PMID: 35430670.

    Read at: PubMed
  • Published on 4/11/2022

    Parikh RB, Takvorian SU, Vader D, Paul Wileyto E, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA. Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. J Natl Cancer Inst. 2022 Apr 11; 114(4):571-578. PMID: 34893865.

    Read at: PubMed
  • Published on 12/7/2021

    Calip GS, Wadé NB, Guadamuz JS, Wang X, Miksad RA, Whitaker KD. Disparities in cardiovascular disease mortality after breast cancer treatment: Methodological considerations using real-world data. Cancer. 2022 02 15; 128(4):647-650. PMID: 34873685.

    Read at: PubMed
  • Published on 10/7/2021

    Kelley RK, Miksad R, Cicin I, Chen Y, Klümpen HJ, Kim S, Lin ZZ, Youkstetter J, Hazra S, Sen S, Cheng AL, El-Khoueiry AB, Meyer T, Abou-Alfa GK. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. Br J Cancer. 2022 03; 126(4):569-575. PMID: 34621044.

    Read at: PubMed
  • Published on 9/23/2021

    Parikh RB, Takvorian SU, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA. Impact of the COVID-19 pandemic on treatment patterns for US patients with metastatic solid cancer. medRxiv. 2021 Sep 23. PMID: 34611665.

    Read at: PubMed
  • Published on 8/31/2021

    Stein SM, Snider J, Ali SM, Miksad RA, Alexander BM, Castellanos E, Schrock AB, Madison R, Swaminathan A, Venstrom JM, McCusker M. Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. Future Oncol. 2021 Nov; 17(31):4101-4114. PMID: 34463133.

    Read at: PubMed
  • Published on 7/31/2021

    Tan K, Bryan J, Segal B, Bellomo L, Nussbaum N, Tucker M, Torres AZ, Bennette C, Capra W, Curtis M, Miksad RA. Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data. Clin Pharmacol Ther. 2022 01; 111(1):168-178. PMID: 34197637.

    Read at: PubMed
  • Published on 7/23/2021

    Bockorny B, Bullock AJ, Abrams TA, Faintuch S, Alsop DC, Goldberg SN, Ahmed M, Miksad RA. Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma. Dig Dis Sci. 2022 Jul; 67(7):3455-3463. PMID: 34297268.

    Read at: PubMed
  • Published on 7/6/2021

    Miksad RA, Calip GS. Early-onset pancreatic cancer research: Making sense of confounding and bias. Cancer. 2021 10 01; 127(19):3505-3507. PMID: 34228811.

    Read at: PubMed
  • Published on 6/17/2021

    Calip GS, Miksad RA, Sarkar S. Time-Related Biases in Nonrandomized COVID-19-Era Studies Using Real-world Data. JAMA Oncol. 2021 Jun 17. PMID: 34137793.

    Read at: PubMed

View 72 more publications: View full profile at BUMC

View all profiles